HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Permissions Request Permissions Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (1) Citing Articles via Google Scholar Google Scholar Articles by de Visser, Y. P. Articles by Wagenaar, G. T. M. Search for Related Content PubMed PubMed Citation Articles by de Visser, Y. P. Articles by Wagenaar, G. T. M.

Phosphodiesterase-4 inhibition attenuates pulmonary inflammation in neonatal lung injury

¹ Dept of Pediatrics, Division of Neonatology, Leiden University Medical Center, Leiden, the Netherlands, ² Dept of Pediatrics, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA, USA.

CORRESPONDENCE: G. T. M. Wagenaar, Dept of Pediatrics, Division of Neonatology, P3-P30, Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden, The Netherlands. Fax: 31 715266876. E-mail: g.t.m.wagenaar{at}lumc.nl

Keywords: Bronchopulmonary dysplasia, coagulation, fibrin deposition, oxidative stress, piclamilast, rolipram

Received: June 14, 2007
Accepted November 28, 2007

Phosphodiesterase-4 (PDE4) inhibitors may offer novel therapeutic strategies in respiratory diseases, including asthma and chronic obstructive pulmonary disease. Therefore, selective PDE4 inhibitors may also provide a therapeutic option for very pre-term infants with bronchopulmonary dysplasia (BPD). The anti-inflammatory effect of two PDE4 inhibitors was investigated in a pre-term rat model of hyperoxia-induced lung injury.

Pre-term rat pups were exposed to room air, hyperoxia, or hyperoxia and one of two PDE4 inhibitors: rolipram and piclamilast. The anti-inflammatory effects of prolonged PDE4 inhibitor therapy were investigated by studying survival, histopathology, fibrin deposition, alveolar vascular leakage and differential mRNA expression (real-time RT-PCR) of key genes involved in inflammation, alveolar enlargement, coagulation and fibrinolysis.

PDE4 inhibitor therapy prolonged median survival by up to 7 days and reduced alveolar fibrin deposition, lung inflammation and vascular leakage by decreasing the influx of monocytes and macrophages and protein efflux in bronchoalveolar lavage fluid. Analysis of mRNA expression of key genes involved in experimental BPD revealed a significant PDE4 inhibitor-induced improvement of genes involved in inflammation, fibrin deposition and alveolarisation.

In conclusion, phosphodiesterase-4 inhibition prolongs survival by inhibiting inflammation and reducing alveolar fibrin deposition in pre-term rat pups with neonatal hyperoxic lung injury, whereby piclamilast outperformed rolipram.

This article has been cited by other articles:

				K. Woyda and R. T. Schermuly From the authors Eur. Respir. J., May 1, 2009; 33(5): 1237 - 1237. [Full Text] [PDF]

				K. Woyda, S. Koebrich, I. Reiss, S. Rudloff, S. S. Pullamsetti, A. Ruhlmann, N. Weissmann, H. A. Ghofrani, A. Gunther, W. Seeger, et al. Inhibition of phosphodiesterase 4 enhances lung alveolarisation in neonatal mice exposed to hyperoxia Eur. Respir. J., April 1, 2009; 33(4): 861 - 870. [Abstract] [Full Text] [PDF]